R547 - CDK 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemER547Cat. No.: HY-10014CAS No.: 741713-40-6分式: CHFNOS分量: 441.45作靶点: CDK作通路: Cell Cycle/DNA Damage储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (113.26 mM)H2O : 40% PEG300 5% Tween

2、-80 45% salineSolubility: 2.5 mg/mL (5.66 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.66 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 R547是ATP竞争性CDK1，2，4抑制剂，Ki分别为2 nM，3 nM和1 nM。IC50 & Target Cdk1/cyclin B CDK4/cyclin D

3、CDK2/cyclinE2 nM (Ki) 1 nM (Ki) 3 nM (Ki)户使本产品发表的科研献 Science. 2017 Dec 1;358(6367). Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer

4、P, Yin X, Smith MA, HigginsBX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.Discovery of 4-Amino-2-(1-methanesulfonylpiperidin-42. Bays M, Rabasseda X, Prous JR.Gateways to clinical trials.Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37.3. Martin F, Thomson TM, Sew

5、er A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC.Assessment of networkperturbation amplitudes by applying high-throughput data to causal biological networks.BMC Syst Biol. 2012 May 31;6:54.4. DePinto, Wanda et al In vitro and in vivo activity of R547: a potent and selective cycli

6、n-dependent kinase inhibitor currently in phase Iclinical trials Molecular Cancer Therapeutics (2006), 5(11), 2644-26585. Jones, Clifford D.; Andrews, David M. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitorsBioorganic & Medicinal Chemistry Letters (2008), 18(24), 6486-6489McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 4